Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003116 · ClinicalTrials.gov registry record · Phase 2
High-Dose Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
A Phase 2 study, sponsored by Case Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 66
- Enrollment target
NCT00003116 is a Phase 2 study that has completed, run by Case Comprehensive Cancer Center. The registered enrollment target is 66 participants.
The verdict
NCT00003116, a Phase 2 study, has completed, sponsored by Case Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 66 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: This phase II trial is studying how well giving busulfan, cyclophosphamide, and filgrastim together with peripheral stem cell transplantation from a sibling donor works in treating patients with hematologic cancer.
Interventions
- DRUG cyclophosphamide
- BIOLOGICAL filgrastim
- DRUG busulfan
- DRUG cyclosporine
- PROCEDURE bone marrow ablation with stem cell support
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 1997-05 |
| Est. Completion | 2009-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003116
The ClinicalTrials.gov registry entry for NCT00003116 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00003116 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003116 about?
NCT00003116 is a clinical study titled "High-Dose Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: This phase II ...
What is the current status of trial NCT00003116?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 66 participants. The study started on 1997-05. Estimated completion is 2009-06.
What interventions are being tested in trial NCT00003116?
The interventions under investigation include: cyclophosphamide (DRUG), filgrastim (BIOLOGICAL), busulfan (DRUG), cyclosporine (DRUG), bone marrow ablation with stem cell support (PROCEDURE).
Who is sponsoring clinical trial NCT00003116?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.